Funds › Squadron Capital Management LLC
Squadron Capital Management LLC
13F for Q2 2026, filed Aug 14, 2026. 34 positions worth $322.2M.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Squadron Capital Management LLC in the latest 13F quarter?
Using 13F.ai, how has Squadron Capital Management LLC's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Squadron Capital Management LLC's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q2 2026
Largest first. Common shares only; puts and calls are under All positions.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | RLMD Relmada Therapeutics, Inc. | 7.35M | $50.9M | 15.8% | -13.3% | 13F ↗ |
| 2 | CCCC C4 Therapeutics, Inc. | 7.20M | $33.6M | 10.4% | +220% | 13F ↗ |
| 3 | COGT Cogent Biosciences, Inc. | 865,000 | $33.5M | 10.4% | +9.8% | 13F ↗ |
| 4 | KOD Kodiak Sciences Inc | 500,000 | $19.5M | 6.0% | +31.6% | 13F ↗ |
| 5 | RLAY Relay Therapeutics, Inc. | 970,000 | $18.1M | 5.6% | +44.2% | 13F ↗ |
| 6 | ZNTL Zentalis Pharmaceuticals, Inc. | 3.70M | $17.9M | 5.6% | +1.9% | 13F ↗ |
| 7 | EWTX Edgewise Therapeutics, Inc. | 290,000 | $11.8M | 3.7% | -17.1% | 13F ↗ |
| 8 | MAZE Maze Therapeutics, Inc. | 335,000 | $10.0M | 3.1% | +30.1% | 13F ↗ |
| 9 | IVA Inventiva S.A. · ADR | 2.44M | $9.2M | 2.9% | +355% | 13F ↗ |
| 10 | ANL Adlai Nortye Group Ltd. · ADR | 764,876 | $8.8M | 2.7% | -39.5% | 13F ↗ |
| 11 | ELVN Enliven Therapeutics, Inc. | 160,000 | $8.1M | 2.5% | New | 13F ↗ |
| 12 | PALI Palisade Bio, Inc. | 3.00M | $6.3M | 1.9% | Unchanged | 13F ↗ |
| 13 | IKT Inhibikase Therapeutics, Inc. | 3.00M | $6.1M | 1.9% | -14.3% | 13F ↗ |
| 14 | ADAG Adagene Inc. | 1.25M | $5.3M | 1.6% | New | 13F ↗ |
| 15 | Forte Biosciences Inc | 225,000 | $4.8M | 1.5% | New | 13F ↗ |
| 16 | IFRX InflaRx N.V. | 2.00M | $4.5M | 1.4% | New | 13F ↗ |
| 17 | ASMB Assembly Biosciences, Inc. | 160,000 | $4.4M | 1.4% | New | 13F ↗ |
| 18 | PMN ProMIS Neurosciences Inc. | 324,977 | $4.3M | 1.3% | Unchanged | 13F ↗ |
| 19 | CTNM Contineum Therapeutics, Inc. | 260,000 | $4.3M | 1.3% | New | 13F ↗ |
| 20 | CMPS COMPASS Pathways Plc · ADR | 300,000 | $4.2M | 1.3% | New | 13F ↗ |
| 21 | DFTX Definium Therapeutics, Inc. | 85,000 | $4.0M | 1.2% | New | 13F ↗ |
| 22 | SLGL Sol-Gel Technologies Ltd. | 52,000 | $3.9M | 1.2% | +67.7% | 13F ↗ |
| 23 | BIOA BioAge Labs, Inc. | 155,000 | $3.8M | 1.2% | New | 13F ↗ |
| 24 | SCYX SCYNEXIS, Inc. | 756,884 | $3.1M | 1.0% | New | 13F ↗ |
| 25 | PRQR ProQR Therapeutics N.V. · Shs Euro | 1.51M | $2.8M | 0.9% | New | 13F ↗ |
| 26 | RZLT Rezolute, Inc. | 403,410 | $2.1M | 0.7% | New | 13F ↗ |
| 27 | LPCN Lipocine Inc. | 810,000 | $2.1M | 0.6% | +80.0% | 13F ↗ |
| 28 | CUE Cue Biopharma, Inc. | 50,000 | $1.6M | 0.5% | New | 13F ↗ |
| 29 | Calcimedica Inc | 1.24M | $1.3M | 0.4% | New | 13F ↗ |
| 30 | IRLA IRulya Therapeutics Inc. | 40,375 | $734.4K | 0.2% | New | 13F ↗ |
| 31 | KTTA Pasithea Therapeutics Corp. | 1.00M | $515.4K | 0.2% | -52.4% | 13F ↗ |
| 32 | INM InMed Pharmaceuticals Inc. | 325,000 | $503.8K | 0.2% | New | 13F ↗ |
| 33 | NMRA Neumora Therapeutics, Inc. | 100,000 | $170.0K | 0.1% | New | 13F ↗ |
| 34 | NXTC NextCure, Inc. | 64,464 | $103.1K | <0.1% | -75.7% | 13F ↗ |
Changes since Q1 2026
17 new, 9 added to, 6 trimmed, 13 exited, 2 unchanged. By estimated dollars.
New positions (17)
| ELVN Enliven Therapeutics, Inc. | 160,000 | New | $8.1M |
| ADAG Adagene Inc. | 1.25M | New | $5.3M |
| Forte Biosciences Inc | 225,000 | New | $4.8M |
| IFRX InflaRx N.V. | 2.00M | New | $4.5M |
| ASMB Assembly Biosciences, Inc. | 160,000 | New | $4.4M |
| CTNM Contineum Therapeutics, Inc. | 260,000 | New | $4.3M |
| CMPS COMPASS Pathways Plc · ADR | 300,000 | New | $4.2M |
| DFTX Definium Therapeutics, Inc. | 85,000 | New | $4.0M |
| BIOA BioAge Labs, Inc. | 155,000 | New | $3.8M |
| SCYX SCYNEXIS, Inc. | 756,884 | New | $3.1M |
Added to (9)
| CCCC C4 Therapeutics, Inc. | 7.20M | +220% | $23.1M |
| IVA Inventiva S.A. · ADR | 2.44M | +355% | $7.2M |
| RLAY Relay Therapeutics, Inc. | 970,000 | +44.2% | $5.6M |
| KOD Kodiak Sciences Inc | 500,000 | +31.6% | $4.7M |
| COGT Cogent Biosciences, Inc. | 865,000 | +9.8% | $3.0M |
| MAZE Maze Therapeutics, Inc. | 335,000 | +30.1% | $2.3M |
| SLGL Sol-Gel Technologies Ltd. | 52,000 | +67.7% | $1.6M |
| LPCN Lipocine Inc. | 810,000 | +80.0% | $921.6K |
| ZNTL Zentalis Pharmaceuticals, Inc. | 3.70M | +1.9% | $334.6K |
Trimmed (6)
Exited (13)
| Kalvista Pharmaceuticals Inc | 985,100 | Exited | -$19.8M |
| ABVX Abivax SA · ADR | 130,000 | Exited | -$14.5M |
| NKTR Nektar Therapeutics | 125,000 | Exited | -$9.0M |
| Scynexis Inc | 7.61M | Exited | -$7.0M |
| EPRX Eupraxia Pharmaceuticals Inc. · Com 298736 Al 3 Euronet Worldwide Inc Note 0.750% 3/1 | 680,000 | Exited | -$4.9M |
| GHRS GH Research PLC | 325,000 | Exited | -$4.6M |
| ALXO ALX Oncology Holdings Inc. | 1.46M | Exited | -$2.9M |
| CNTX Context Therapeutics Inc. | 1.10M | Exited | -$2.9M |
| TRAW Traws Pharma, Inc. | 511,714 | Exited | -$936.4K |
| TXMD TherapeuticsMD, Inc. | 420,421 | Exited | -$849.3K |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
All positions
Search, sort and filter every position, with puts and calls on their own tab. Premium plan.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q2 2026.
Filings
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer